Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSabre Insurance Group Regulatory News (SBRE)

Share Price Information for Sabre Insurance Group (SBRE)

Share Price is delayed by 15 minutes
Get Live Data
157.60    3.80 (2.47%)
Bid:
157.60
Ask:
158.00
Spread: 0.40 (0.254%)
Market Cap: £385.03m
SBRE Live PriceLast checked at - London Stock Exchange

Intraday Sabre Insurance Group Share Chart

Trading Update

10 Oct 2019 07:00

RNS Number : 3561P
Sabre Insurance Group PLC
10 October 2019
 

10 October 2019

 

SABRE INSURANCE GROUP PLC

Trading Update

Sabre Insurance Group plc (the "Group", or "Sabre"), one of the UK's leading private motor insurance underwriters, today provides a trading update for the nine months ending 30 September 2019.

Summary

·; The Group continues to execute its strategy of focusing on underwriting profitability over premium growth in order to maximise profitability over the long term.

·; The Group anticipates delivering a FY2019 combined ratio slightly better than our mid 70%'s target (FY2018: 70.6%).

·; As anticipated, gross written premiums (GWP) for the first nine months of the year are lower year-on-year at £152.9m(1) (2018: £162.6m). The Group expects full year GWP to be approximately 7% lower than 2018 (FY2018: £210.0m), in line with previous guidance.

·; Disciplined underwriting and well controlled claims management have successfully mitigated the anticipated ongoing increase in claims inflation and other cost pressures.

·; Strong organic capital generation supports the potential for an attractive full year dividend with a solvency coverage ratio of 198%(1) as at the end of September 2019 (2018: 195%), above our 140% to 160% target range.

 

Geoff Carter, Chief Executive Officer, commented:

Throughout a period of significant change in the UK motor insurance sector, we have continued to apply our long-term strategy, to focus on underwriting profitability, with premium volume remaining an output rather than a target.

We continue to observe high levels of industry-wide claims inflation, and are additionally focused on other emerging cost pressures. These include increases in the MIB and FSCS levies, potential reinsurance price rises following the Ogden rate decision and possible changes in claims management company behaviour following the implementation of the forthcoming personal injury legal reforms.

Encouragingly, early signs of market premium increases or other competitor actions mean that while we have accelerated price increases to cover these emerging costs as well as ongoing inflation, our volumes are not being further negatively impacted.

We note the recent FCA report on pricing in the insurance industry. Given Sabre's approach is to price policies on a consistent basis across our new and renewal portfolios we do not anticipate that the proposed remedies will have a detrimental impact on our business.

Our performance so far in this financial year has been in line with our expectations and we remain confident that we will deliver a combined ratio slightly below our long-term target and an attractive dividend for the full year, supported by our current solvency ratio of 198%, which is well above our target 140% to 160% range.

(1) Numerical information not subject to audit

 

 

Investor enquiries

Sabre Insurance Group plc

Adam Westwood, Chief Financial Officer

adam.westwood@sabre.co.uk

01306 747 272

Media enquiries

Tulchan Communications LLP

James Macey White and Amber Ahluwalia

020 7353 4200

sabre@tulchangroup.com

 

 

LEI code: 2138006RXRQ8P8VKGV98

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTLLFEEITLAIIA
Date   Source Headline
2nd Jun 20267:00 amRNSOn-market Share Buyback Programme of £5m
27th May 20269:36 amRNSDirector Declaration
21st May 202611:20 amRNSResult of AGM
21st May 20267:00 amRNSTrading Update
12th May 20261:22 pmRNSDirector/PDMR Shareholding
22nd Apr 20261:18 pmRNSDirector/PDMR Shareholding
14th Apr 20263:48 pmRNSDirector/PDMR Shareholding
13th Apr 20263:18 pmRNSDirector/PDMR Shareholding
8th Apr 20262:56 pmRNSDirector/PDMR Shareholding
8th Apr 202610:41 amRNSDirector/PDMR Shareholding
8th Apr 202610:39 amRNSDirector/PDMR Shareholding
30th Mar 202611:01 amRNSNotice of AGM
11th Mar 20261:49 pmRNSDirector/PDMR Shareholding
10th Mar 20267:00 amRNSFull-year results 2025
11th Feb 20261:27 pmRNSDirector/PDMR Shareholding
13th Jan 20263:43 pmRNSDirector/PDMR Shareholding
11th Dec 20251:29 pmRNSDirector/PDMR Shareholding
11th Nov 20251:40 pmRNSDirector/PDMR Shareholding
31st Oct 20258:00 amRNSTotal Voting Rights
23rd Oct 20259:58 amRNSDirector/PDMR Shareholding
16th Oct 20257:00 amRNSTrading Update
14th Oct 20257:49 amRNSHolding(s) in Company
13th Oct 20253:56 pmRNSDirector/PDMR Shareholding
3rd Oct 20257:00 amRNSCompletion of Buyback Programme
3rd Oct 20257:00 amRNSTransaction in Own Shares
2nd Oct 20257:00 amRNSTransaction in Own Shares
1st Oct 20257:00 amRNSTransaction in Own Shares
30th Sep 202510:21 amRNSTotal Voting Rights
30th Sep 20257:00 amRNSTransaction in Own Shares
29th Sep 20257:00 amRNSTransaction in Own Shares
26th Sep 20257:00 amRNSTransaction in Own Shares
25th Sep 20251:01 pmRNSDirector/PDMR Shareholding
25th Sep 20257:00 amRNSTransaction in Own Shares
24th Sep 20257:00 amRNSTransaction in Own Shares
23rd Sep 20257:00 amRNSTransaction in Own Shares
22nd Sep 20257:00 amRNSTransaction in Own Shares
19th Sep 20257:00 amRNSTransaction in Own Shares
18th Sep 20254:52 pmRNSHolding(s) in Company
18th Sep 20257:00 amRNSTransaction in Own Shares
17th Sep 20257:00 amRNSTransaction in Own Shares
16th Sep 20257:00 amRNSTransaction in Own Shares
15th Sep 20257:00 amRNSTransaction in Own Shares
12th Sep 20257:00 amRNSTransaction in Own Shares
11th Sep 202512:24 pmRNSDirector/PDMR Shareholding
11th Sep 20257:00 amRNSTransaction in Own Shares
10th Sep 20257:00 amRNSTransaction in Own Shares
9th Sep 20257:00 amRNSTransaction in Own Shares
8th Sep 20257:00 amRNSTransaction in Own Shares
5th Sep 20257:00 amRNSTransaction in Own Shares
4th Sep 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.